RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Regulatory Update: FDA Steps Up Debarment and Disqualification Efforts

Regulatory Update: FDA Steps Up Debarment and Disqualification Efforts

Posted 01 September 2009 | By

The US Food and Drug Administration (FDA) recently enhanced its procedures for debarment and disqualification of noncompliant investigators and others as another step toward protecting clinical trial participants and ensuring the safety and effectiveness of the medical products marketed in the US.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.